Publication | Closed Access

Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis

Clinical TherapeuticHealth-related QualityClinical TrialsPlaque PsoriasisClinical DermatologyPharmacotherapyDermatologyExperimental DermatologyMedicine